BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · IEX Real-Time Price · USD
2.710
-0.260 (-8.75%)
Apr 24, 2024, 4:00 PM EDT - Market closed
BioXcel Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for BTAI stock have an average target of 6.00, with a low estimate of 4.00 and a high estimate of 10. The average target predicts an increase of 121.40% from the current stock price of 2.71.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for BTAI stock from 8 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 5 | 5 | 5 | 6 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +269.00% | Apr 23, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +305.90% | Mar 18, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $18 → $7 | Strong Buy | Maintains | $18 → $7 | +158.30% | Mar 14, 2024 |
| B of A Securities | B of A Securities | Strong Buy Maintains $8 → $7 | Strong Buy | Maintains | $8 → $7 | +158.30% | Mar 13, 2024 |
| UBS | UBS | Strong Buy → Hold Downgrades $9 → $4 | Strong Buy → Hold | Downgrades | $9 → $4 | +47.60% | Feb 21, 2024 |
Financial Forecast
Revenue This Year
3.64M
from 1.38M
Increased by 163.62%
Revenue Next Year
14.06M
from 3.64M
Increased by 286.42%
EPS This Year
-2.84
from -6.15
EPS Next Year
-2.10
from -2.84
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 7.4M | 19.8M | 61.8M | 161.4M | 237.3M |
| Avg | 3.6M | 14.1M | 43.6M | 84.1M | 160.6M |
| Low | 2.0M | 7.3M | 22.4M | 2.0M | 87.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 432.6% | 444.3% | 339.9% | 270.2% | 182.3% |
| Avg | 163.6% | 286.4% | 210.1% | 92.9% | 91.0% |
| Low | 44.1% | 99.3% | 59.6% | -95.5% | 3.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.66 | -0.93 | -0.70 | 0.12 | 1.14 |
| Avg | -2.84 | -2.10 | -1.39 | -0.57 | 0.67 |
| Low | -3.61 | -3.20 | -2.28 | -1.16 | 0.22 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.